#Baraclude

Researchers have challenged findings from a Chinese study that concluded Baraclude is tied to a lower risk of liver cancer.

People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.

Some study participants experienced hepatitis B surface antigen loss, considered a functional cure.

South Korean researchers found no difference in the rates of liver cancer, liver transplant or death based on the treatment used.

The drug is still associated with a lower liver cancer rate than Baraclude.

A quick overview of our reporting on the 53rd International Liver Congress in Vienna

People who took Viread were about two thirds less likely to develop HCC, but this could be related to other factors as well.

People who added ABI-H0731 saw greater viral load reductions than those who used nucleoside/nucleotide analogues alone.

Researchers analyzed a cohort of South Koreans taking Viread (tenofovir disoproxil fumarate) or Baraclude (entecavir) for hepatitis B.

This includes a higher risk of liver cancer, cirrhosis-related complications and death.

The exception is those people with hepatitis B and liver cancer.

However, no such difference was seen among those with cirrhosis or those whose virus was not well treated.

Low but detectable HBV DNA during antiviral therapy is associated with detrimental long-term outcomes.